Summary: The global market for generic drugs was valued at $REDACTED billion in 2022. The market is forecast to grow from $REDACTED billion in 2023 at a compound annual growth rate (CAGR) of REDACTED% to reach approximately $REDACTED billion by the end of 2028. The increasing patent cliffs and exclusivities, favorable regulatory policies, and positive changes in prescription patterns are responsible for market growth. This report segments the global market by molecule type and region. The market is categorized into small-molecule drugs and biosimilars based on molecule type. The small molecule drugs segment, which held the largest share in 2022, is expected to grow at a REDACTED% CAGR during the forecast period. This segment’s large share is attributed to the growing medical needs of chronically ill patients. The biosimilars segment is growing at a higher CAGR, REDACTED%, during the forecast period. The increasing prevalence of cancer and immunological diseases drives the need for low-cost biosimilars. Some companies in this market include Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Ltd., and Fresenius Kabi. Report Scope: The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The report covers small molecule drugs and biosimilars. It includes market drivers and challenges in the generic drug industry. The competitive landscape includes generic drug sales of key competitors and their ranking in the market. It also covers the emerging trends in the generic drugs industry. By geographical region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes countries such as the U.S., Canada and Mexico; Europe includes Germany, U.K., Italy, and Rest of Europe; Asia-Pacific includes China, India, Japan, and Rest of Asia-Pacific. The estimated values used are based on drug manufacturers’ total revenues. Report Includes: - 37 data tables and 39 additional tables - An overview of the global markets for generic (pharmaceutical) drugs - Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 - Estimate of the market size and revenue forecast of the market for generic drugs, and corresponding market share analysis based on molecule type and geographic region - Evaluation of the current and future market potential of generic drugs, as well as the major generics, regulatory landscape and patent cliff within the biopharmaceutical industry - Discussion of the major market drivers, opportunities and challenges, emerging technologies, and regulations - Data and market value analyses for the U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan - Overview of the sustainability trends and factors in the market for generic drugs, with emphasis on consumer attitudes, ESG scores, case studies and the ESG practices of leading companies - Analysis of the pipeline for new generic drugs and their impact on the growth of the overall biopharmaceutical products market - Patent review and analysis of key patent grants - An analysis of the industry structure, including company market shares, recent M&A activity, and venture funding - Analysis of the top market players, their global rankings, recent developments, key financials and segmental revenues, and product portfolios - Profiles of the leading market players